Compare LIVN & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIVN | TMDX |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.4B |
| IPO Year | 2015 | 2019 |
| Metric | LIVN | TMDX |
|---|---|---|
| Price | $66.99 | $113.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $72.43 | ★ $148.22 |
| AVG Volume (30 Days) | 655.4K | ★ 851.2K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 4.87 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | $9.79 | $24.51 |
| Revenue Next Year | $6.63 | $18.72 |
| P/E Ratio | ★ N/A | $23.79 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $34.75 | $88.50 |
| 52 Week High | $71.58 | $156.00 |
| Indicator | LIVN | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 60.19 | 50.19 |
| Support Level | $61.63 | $109.43 |
| Resistance Level | $67.92 | $131.86 |
| Average True Range (ATR) | 1.97 | 5.25 |
| MACD | 0.46 | 2.02 |
| Stochastic Oscillator | 84.53 | 72.52 |
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.